SLP
$62.46
Simulations Plus
($1.11)
(1.75%)
SLP
Earnings Whisper ®
N/A
4th Quarter August 2020
Consensus:  $0.05
Revenue:  N/A
Thursday
Oct 8
4:35 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SLP reports earnings?
Beat
Meet
Miss

Where is SLP's stock price going from here?
Up
Flat
Down
Stock chart of SLP
Analysts
Summary of analysts' recommendations for SLP
Score
Grade
Pivots
Resistance
$72.84
$70.62
$66.54

$64.32

Support
$60.24
$58.02
$53.94
Tweet
Growth
Description
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
Peers
SalesforceActivision BlizzardMicrosoftOracleTake-Two Interactive SoftwareCyberArkAdobeAutodeskIntuitPaylocity Holding